Derriford Hospital
Derriford Hospital
Plymouth, United Kingdom27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06635824 | |
| Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, iron metabolism disease, iron poisoning, metabolic disease | Recruiting | Phase 2 | 2026-09-16 | NCT07332091 | |
| CGM Use in Adults With Type 2 Diabetes on Basal Insulin | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Not applicable | 2026-08-21 | NCT05944432 | |
| A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-08-12 | NCT04307576 | |
| A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome | B-cell neoplasm, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Richter transformation, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-08-07 | NCT03899337 | |
| "Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment" (PROTECT-HF) | Arrhythmias, Cardiac, Bradycardia, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder | Recruiting | Not applicable | 2026-07-22 | NCT05815745 | |
| Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 2 | 2026-06-22 | NCT05004064 | |
| Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-06-17 | NCT05093231 | |
| A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-16 | NCT05463263 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2026-05-07 | NCT04116047 | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-05-05 | NCT04217278 | |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-30 | NCT04546620 | |
| Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers | differentiated thyroid carcinoma | Recruiting | Not applicable | 2026-03-05 | NCT05604963 | |
| Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer | estrogen-receptor positive breast cancer | Active, not recruiting | Phase 1 / Phase 2 | 2025-11-26 | NCT01992952 | |
| A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | metastatic prostate carcinoma | Recruiting | Phase 3 | 2025-09-26 | NCT06320067 | |
| POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2025-07-10 | NCT02401685 | |
| ORANGE SEGMENTS: Open Versus Laparoscopic Parenchymal Preserving Postero-Superior Liver Segment Resection | Liver Surgery | Active, not recruiting | Not applicable | 2025-05-19 | NCT03270917 | |
| Ambroxol to Slow Progression in Parkinson Disease | Nutritional and Metabolic Diseases, Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, proteostasis deficiencies, synucleinopathy | Recruiting | Phase 3 | 2025-05-01 | NCT05778617 | |
| Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2025-04-16 | NCT05635162 | |
| Oxford Pre-cancerous Lymphoproliferative Disorders Study | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Not stated | 2025-02-03 | NCT04023747 | |
| Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2024-12-05 | NCT01566240 | |
| Prostate Advances in Comparative Evidence | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2024-01-19 | NCT01584258 | |
| Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), central nervous system cancer, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Active, not recruiting | Phase 3 | 2023-09-11 | NCT00626990 | |
| The European NAFLD Registry | Body Weight, Digestive System Diseases, Digestive System Neoplasms, Dyslipidemias, Fibrosis, Fibrosis, Liver, Lipid Metabolism Disorders, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Steatohepatitis, adenocarcinoma, carcinoma, cardiovascular disorder, cirrhosis of liver, diabetes mellitus, endocrine system disorder, epithelial neoplasm, fatty liver disease, glucose metabolism disease, hepatocellular carcinoma, hypertensive disorder, liver disorder, metabolic disease, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, neoplasm, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, vascular disorder | Recruiting | Not stated | 2023-01-06 | NCT04442334 |